echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > GUT: The long-term effects of drug therapy on the health outcomes of future generations in pregnant women with inflammatory bowel disease.

    GUT: The long-term effects of drug therapy on the health outcomes of future generations in pregnant women with inflammatory bowel disease.

    • Last Update: 2020-10-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, researchers examined the long-term health outcomes of offspring of mothers with inflammatory bowel disease (IBD) and assessed the effects of IBD treatment drugs on the health outcomes of future generations.
    conducted a multi-center retrospective study in the Netherlands.
    between 1999 and 2018, IBD-delivered mothers from 20 hospitals participated.
    information on the characteristics of a child's disease, drug use, lifestyle, pregnancy and long-term health outcomes is collected from the mother's and child's medical records until the child is 5 years of age.
    of the study was to assess infection rates, and the secondary endpoint was to assess vaccination, growth, autoimmune diseases and malignant tumor events.
    626 women and 1,000 children with IBD participated in the study, 381 had Crohn's disease (CD, 61%), 225 had ulcerative colitis (UC, 36%) and 20 had unclassified IBD (3%).
    196 (20 per cent) the mothers of newborns received anti-tumor necrotoxytic drugs during pregnancy, 240 cases of thiopental monotherapy (24 per cent), 60 other drugs were received simultaneously in thiopental, and 564 mothers of newborns did not receive anti-tumor necrotum cause drugs and or thiopental (as a control group) during pregnancy.
    study found that exposure to in-house IBD drugs was not associated with poor long-term health outcomes in future generations.
    use of thiopental during pregnancy leads to an increase in bile siltation (ICP) in the maternal liver, but does not affect birth outcomes and long-term health outcomes in children.
    study concluded that for pregnant women with inflammatory bowel disease, receiving anti-inflammatory bowel disease medication during pregnancy does not lead to abnormal health in future generations.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.